BRIEF RESEARCH REPORT article
Front. Pharmacol.
Sec. Drugs Outcomes Research and Policies
Volume 16 - 2025 | doi: 10.3389/fphar.2025.1542837
This article is part of the Research TopicBone Marrow Failure Syndromes: From Biology to Cure - Volume IIView all articles
Recombinant human thrombopoietin improves hematopoietic stem cell differentiation and T-cell immune homeostasis in patients with severe aplastic anemia by upregulating c-MPL
Provisionally accepted- 1Department of Hematology, Tianjin Medical University General Hospital, Tianjin, China
- 2Department of Respiratory, Tianjin Medical University General Hospital Airport Hospital, Tianjin, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background: Recombinant human thrombopoietin (rhTPO) regulates platelet production by promoting megakaryocyte proliferation and has shown promising therapeutic effects in hematopoietic recovery for severe aplastic anemia (SAA). However, its potential impact on immune cells remains unclear. Methods: This study included 23 patients with SAA, who were divided into two groups based on whether they received rhTPO. Flow cytometry was used to assess the proportions of peripheral immune cells and hematopoietic stem cells (HSCs), as well as their c-MPL expression. Further validation was performed by in vitro culture experiments and SAA mice. Results: The rhTPO group exhibited an upward trend in platelet counts (PLT), as well as a higher proportion of peripheral CD4+ T cells and an increased CD4+/CD8+ T cell ratio. The expression of the receptor of rhTPO, c-MPL, was significantly increased on CD4+ T cells and regulatory T cells (Tregs). More important is we found c-MPL expression on bone marrow CD34+ cells was unregulated in the rhTPO group. In vitro stimulation of bone marrow mononuclear cells from patients with SAA using rhTPO elevated the proportion of Tregs and the CD4+/CD8+ T cell ratio. Furthermore, CsA combined with rhTPO treatment in SAA mice significantly restored the proportion of peripheral Tregs. Conclusion: rhTPO can induce the upregulation of c-MPL expression on HSCs, CD4+ T cells, and Tregs in patients with SAA. It accelerates platelet production and regulates the proliferation of CD4+ T cells and Tregs, thereby promoting immune homeostasis restoration in SAA.
Keywords: Severe aplastic anemia, RhTPO, C-mpl, T-cell immune homeostasis, hematopoietic stem cell
Received: 10 Dec 2024; Accepted: 01 Aug 2025.
Copyright: © 2025 Deng, Liu, Guo, Liu and Fu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Chunyan Liu, Department of Hematology, Tianjin Medical University General Hospital, Tianjin, 300052, China
Rong Fu, Department of Hematology, Tianjin Medical University General Hospital, Tianjin, 300052, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.